惠泰医疗
(688617)
| 流通市值：285.15亿 | | | 总市值：285.15亿 |
| 流通股本：1.42亿 | | | 总股本：1.42亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 704,078,336.74 | 2,583,927,321.09 | 1,867,437,461.29 | 1,213,804,906.53 |
| 营业收入 | 704,078,336.74 | 2,583,927,321.09 | 1,867,437,461.29 | 1,213,804,906.53 |
| 二、营业总成本 | 451,345,627.26 | 1,672,065,165.22 | 1,191,415,119.57 | 752,300,167.35 |
| 营业成本 | 194,140,326.74 | 700,841,947.49 | 500,684,351.08 | 321,558,137.08 |
| 税金及附加 | 9,664,275.09 | 33,678,934.77 | 23,815,894.43 | 15,529,656.4 |
| 销售费用 | 114,613,851.13 | 460,613,793.02 | 333,963,948.57 | 209,259,920.94 |
| 管理费用 | 32,844,888.35 | 118,637,495.73 | 85,922,964.87 | 56,675,950 |
| 研发费用 | 95,376,771.98 | 364,801,511.35 | 255,144,492.49 | 157,232,347.35 |
| 财务费用 | 4,705,513.97 | -6,508,517.14 | -8,116,531.87 | -7,955,844.42 |
| 其中:利息费用 | 520,339.46 | 1,460,385.06 | 981,983.51 | 457,891.25 |
| 其中:利息收入 | 2,786,983.28 | 13,794,942.53 | 10,248,926.85 | 6,413,490.76 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,007,830.77 | 485,745.67 | 669,858.37 | 250,472.99 |
| 加:投资收益 | 9,664,031.12 | 16,938,228.6 | 13,902,185.85 | 7,896,662.55 |
| 资产处置收益 | -334,654.01 | -926,856.07 | -926,169.8 | -1,318.95 |
| 资产减值损失(新) | -4,203,589.85 | -6,547,893.55 | -3,742,777.3 | -3,698,807.74 |
| 信用减值损失(新) | 2,042,026.91 | -16,591,722.12 | -1,345,849.91 | -1,598,422.52 |
| 其他收益 | 4,733,739.88 | 39,338,897.44 | 26,083,393.21 | 18,951,653.65 |
| 四、营业利润 | 265,642,094.3 | 944,558,555.84 | 710,662,982.14 | 483,304,979.16 |
| 加:营业外收入 | 40,895.47 | 184,843.14 | 168,210.04 | 32,844.67 |
| 减:营业外支出 | 155,710.39 | 8,452,999.47 | 5,079,648.38 | 3,997,537.21 |
| 五、利润总额 | 265,527,279.38 | 936,290,399.51 | 705,751,543.8 | 479,340,286.62 |
| 减:所得税费用 | 39,765,232.46 | 128,551,192.99 | 90,932,514.01 | 60,439,614.74 |
| 六、净利润 | 225,762,046.92 | 807,739,206.52 | 614,819,029.79 | 418,900,671.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 225,762,046.92 | 807,739,206.52 | 614,819,029.79 | 418,900,671.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 229,438,737.11 | 820,636,582.43 | 623,303,796.09 | 425,160,981.21 |
| 少数股东损益 | -3,676,690.19 | -12,897,375.91 | -8,484,766.3 | -6,260,309.33 |
| 扣除非经常损益后的净利润 | 225,164,622.94 | 790,875,930.28 | 602,219,386.38 | 410,820,730.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.64 | 5.82 | 4.42 | 3.02 |
| (二)稀释每股收益 | 1.63 | 5.8 | 4.41 | 3.01 |
| 八、其他综合收益 | -454,815.08 | 406,783.21 | 4,244,439.09 | 2,191,973.46 |
| 归属于母公司股东的其他综合收益 | -454,815.08 | 99,330.36 | 1,597,048.22 | -455,417.41 |
| 九、综合收益总额 | 225,307,231.84 | 808,145,989.73 | 619,063,468.88 | 421,092,645.34 |
| 归属于母公司股东的综合收益总额 | 228,983,922.03 | 820,735,912.79 | 624,900,844.31 | 424,705,563.8 |
| 归属于少数股东的综合收益总额 | -3,676,690.19 | -12,589,923.06 | -5,837,375.43 | -3,612,918.46 |
| 公告日期 | 2026-04-24 | 2026-03-25 | 2025-10-25 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |